Ethylene Glycol

Ethylene Glycol

SCHEMBL16047845

O=C1CCCC1(CO)CO.OCCO

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20954654 0.95 SIRT2 (0.33) SIRT2
SCHEMBL8038201 0.88 GRIN2D (0.32)
SCHEMBL6908316 0.75 GRIN2D (0.37) SIRT2
SCHEMBL6908218 0.74 SIRT2 (0.54) SIRT2
SCHEMBL11218707 0.74 SIRT2 (0.54) SIRT2
SCHEMBL8624485 0.71 GRIN2D (0.36)
SCHEMBL20954458 0.71
SCHEMBL6673206 0.70
SCHEMBL6909148 0.69 SIRT2 (0.49) SIRT2
SCHEMBL4131624 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9920016-B2 Process for the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one REXAHN PHARMACEUTICALS, INC. (US) 2018-03-20 US disclosed
US-20170158662-A1 Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One REXAHN PHARMACEUTICALS, INC. (US) 2017-06-08 US disclosed
US-9533958-B2 Process or the preparation of 4-amino 1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-Enyl)-1H-pyrimidin-2-one REXAHN PHARMACEUTICALS, INC. (US) 2017-01-03 US disclosed
EP-2970147-A1 PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R, 5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE Rexahn Pharmaceuticals, Inc. (US) 2016-01-20 EP disclosed
US-20150376142-A1 Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One Ocuphire Pharma, Inc. 2015-12-31 US disclosed
US-9150520-B2 Process for the preparation of 4-amino-1-((1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-hydroxymethyl-cyclopent-2-enyl)-1H-pyrimidin-2-one REXAHN PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
WO-2014145807-A1 PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R, 5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE REXAHN PHARMACEUTICALS, INC. (US) 2014-09-18 WO disclosed
US-20140275537-A1 PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE REXAHN PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150376142-A1 Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One RXFP4, RXFP1, NPY4R SIRT2 2903/4885
US-20140275537-A1 PROCESS FOR THE PREPARATION OF 4-AMINO-1-((1S,4R,5S)-2-FLUORO-4,5-DIHYDROXY-3-HYDROXYMETHYL-CYCLOPENT-2-ENYL)-1H-PYRIMIDIN-2-ONE RXFP4, RXFP1, NPY4R SIRT2 3050/4885
US-20170158662-A1 Process for the Preparation of 4-Amino-1-((1S,4R,5S)-2-Fluoro-4,5-Dihydroxy-3-Hydroxymethyl-Cyclopent-2-Enyl)-1H-Pyrimidin-2-One RXFP4, RXFP1, NPY4R SIRT2 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.